The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Phase I Trial of the Proteasome Inhibitor Bortezomib in Patients With Advanced Solid Tumors With Observations in Androgen-Independent Prostate Cancer
Open accessAbstract
Purpose: To determine the dose-limiting toxicity and maximum-tolerated dose of the proteasome inhibitor bortezomib administered intravenously weekly for 4 every 5 weeks; to determine the bortezomib pharmacokinetics and pharmacodynamics using plasma levels and an assay for 20S proteasome inhibition (PI) in whole blood; to correlate toxicity with bortezomib dose and degree of 20S PI; and to conduct a preliminary determination of the antitumor activity of bortezomib in patients with androgen independent prostate cancer (AIPCa). Patients and Methods: Fifty-three patients (48 with AIPCa) received 128 cycles of bortezomib in doses ranging from 0.13 to 2.0 mg/m 2/dose, utilizing a careful escalation scheme with a continuous reassessment method. Pharmacokinetic and pharmacodynamic studies were performed in 24 patients (at 1.45 to 2.0 mg/m 2). Results: A dose-related 20S PI was seen, with dose-limiting toxicity at 2.0 mg/m 2 (diarrhea, hypotension) occurring at an average 1-hour post-dose of ≥ 75% 20S PI. Other side effects were fatigue, hypertension, constipation, nausea, and vomiting. No relationship was seen between body-surface area and bortezomib clearance over the narrow dose range tested. There was evidence of biologic activity (decline in serum prostate-specific antigen and interleukin-6 levels) at ≥ 50% 20S PI. Two patients with AIPCa had prostate-specific antigen response and two patients had partial response in lymph nodes. Conclusion: The maximum-tolerated dose and recommended phase II dose of bortezomib in this schedule is 1.6 mg/m 2. Biologic activity (inhibition of nuclear factor-kappa B-related markers) and antitumor activity is seen in AIPCa at tolerated doses of bortezomib. This agent should be further explored with chemotherapy agents in advanced prostate cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Classification and Regression Trees.
Gordon, A. D., Breiman, L., Friedman, J. H., Olshen, R. A., & Stone, C. J. (1984) · Biometrics · doi:10.2307/2530946 · Cited by 23,522
Classification and Regression Trees.
Ryzin, J. V., Breiman, L., Friedman, J. H., Olshen, R. A., & Stone, C. J. (1986) · Journal of the American Statistical Association · doi:10.2307/2288003 · Cited by 20,825
Reporting results of cancer treatment
Miller, A. B., Hoogstraten, B., Staquet, M., & Winkler, A. (1981) · Cancer · doi:10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6 · Cited by 7,793
Sherr, C. J. (1996) · Science · doi:10.1126/science.274.5293.1672 · Cited by 5,379 · cited 3×
“giogenesis, and resistance to therapy.(1-13) Bortezomib, a potent and selective proteasome inhibitor, induces apoptosis in androgen-dependent and androgen-independent (PC-3 and DU-145) cell lines, suppresses angiogenesis, invasion, and metastasis in PCa, and exhibits antitumor activity against PC-3 prostate cancer xen…”
An Essential Role for NF-κB in Preventing TNF-α-Induced Cell Death
Beg, A. A., & Baltimore, D. (1996) · Science · doi:10.1126/science.274.5288.782 · Cited by 3,047
Palombella, V. J., Rando, O. J., Goldberg, A. L., & Maniatis, T. (1994) · Cell · doi:10.1016/s0092-8674(94)90482-0 · Cited by 2,096
Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
O'Quigley, J., Pepe, M., & Fisher, L. (1990) · Biometrics · doi:10.2307/2531628 · Cited by 1,577
Hideshima, T., Richardson, P. G. G., Chauhan, D., Palombella, V. J., Elliott, P. J., Adams, J., & Anderson, K. C. (2001) · PubMed · Cited by 1,508
Self-citationProteasome inhibitors: a novel class of potent and effective antitumor agents.
Adams, J., Palombella, V. J., Sausville, E. A., Johnson, J. I., Destree, A. T., Lazarus, D. D., Maas, J., Pien, C. S., Prakash, S., & Elliott, P. J. (1999) · PubMed · Cited by 1,477
Self-citationControl of oncogenesis and cancer therapy resistance by the transcription factor NF-κB
Baldwin, A. S. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11991 · Cited by 1,434
How Proteolysis Drives the Cell Cycle
King, R. W., Deshaies, R. J., Peters, J.-M., & Kirschner, M. W. (1996) · Science · doi:10.1126/science.274.5293.1652 · Cited by 1,273
Modern Applied Statistics with S-PLUS
Venables, W. N., & Ripley, B. D. (1999) · Statistics and Computing · doi:10.1007/978-1-4757-3121-7 · Cited by 978
Bubley, G. J., Carducci, M., Dahut, W., Dawson, N., Daliani, D., Eisenberger, M., Figg, W. D., Freidlin, B., Halabi, S., Hudes, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.11.3461 · Cited by 977
Self-citationOrlowski, R. Z., Stinchcombe, T. E., Mitchell, B. S., Shea, T. C., Baldwin, A. S., Stahl, S., Adams, J., Esseltine, D.-L., Elliott, P. J., Pien, C. S., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.01.133 · Cited by 760
Self-citationHuang, S., Pettaway, C. A., Uehara, H., Bucana, C. D., & Fidler, I. J. (2001) · Oncogene · doi:10.1038/sj.onc.1204535 · Cited by 556
Some practical improvements in the continual reassessment method for phase I studies
Goodman, S. N., Zahurak, M. L., & Piantadosi, S. (1995) · Statistics in Medicine · doi:10.1002/sim.4780141102 · Cited by 472
LeBlanc, R., Catley, L. P., Hideshima, T., Lentzsch, S., Mitsiades, C. S., Mitsiades, N., Neuberg, D. S., Goloubeva, O. G., Pien, C. S., Adams, J., et al. (2002) · PubMed · Cited by 450
Self-citationA phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies.
Aghajanian, C. A., Soignet, S. L., Dizon, D. S., Pien, C. S., Adams, J., Elliott, P. J., Sabbatini, P. J., Miller, V. A., Hensley, M. L., Pezzulli, S., et al. (2002) · PubMed · Cited by 447
Self-citationContinual Reassessment Method: A Likelihood Approach
O'Quigley, J., & Shen, L. Z. (1996) · Biometrics · doi:10.2307/2532905 · Cited by 382
Read, M. A., Neish, A. S., Luscinskas, F. W., Palombella, V. J., Maniatis, T., & Collins, T. (1995) · Immunity · doi:10.1016/1074-7613(95)90030-6 · Cited by 347
Interleukin-6 Is an Autocrine Growth Factor in Human Prostate Cancer
Giri, D., Ozen, M., & Ittmann, M. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63067-2 · Cited by 334
Adhesion molecules in tumor metastasis.
Zetter, B. R. (1993) · PubMed · Cited by 318
Okamoto, M., Lee, C., & Oyasu, R. (1997) · PubMed · Cited by 304
A comparison of two phase I trial designs
Korn, E. L., Midthune, D., Chen, T. T., Rubinstein, L. V., Christian, M. C., & Simon, R. M. (1994) · Statistics in Medicine · doi:10.1002/sim.4780131802 · Cited by 303
Proteasome Inhibition Measurements: Clinical Application
Lightcap, E. S., McCormack, T. A., Pien, C. S., Chau, V., Adams, J., & Elliott, P. J. (2000) · Clinical Chemistry · doi:10.1093/clinchem/46.5.673 · Cited by 301
Self-citationInterleukin-6: A candidate mediator of human prostate cancer morbidity
Twillie, D. A., Eisenberger, M. A., Carducci, M. A., Hseih, W.-S., Kim, W. Y., & Simons, J. W. (1995) · Urology · doi:10.1016/s0090-4295(99)80034-x · Cited by 286
Lou, W., Ni, Z., Dyer, K., Tweardy, D. J., & Gao, A. C. (2000) · The Prostate · doi:10.1002/(sici)1097-0045(20000215)42:3<239::aid-pros10>3.0.co;2-g · Cited by 278
Characterization of the role of IL-6 in the progression of prostate cancer
Chung, T. D., Yu, J. J., Spiotto, M. T., Bartkowski, M., & Simons, J. W. (1999) · The Prostate · doi:10.1002/(sici)1097-0045(19990215)38:3<199::aid-pros4>3.0.co;2-h · Cited by 231
An, W., Hwang, S.-G., Trepel, J., & Blagosklonny, M. (2000) · Leukemia · doi:10.1038/sj.leu.2401812 · Cited by 207
Novel therapies targeting the myeloma cell and its bone marrow microenvironment
HIDESHIMA, T. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90033-8 · Cited by 201
Borsellino, N., Belldegrun, A. S., & Bonavida, B. (1995) · PubMed · Cited by 171
Keller, E. T., Chang, C., & Ershler, W. B. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.42.26267 · Cited by 166
Expression of the interleukin 6 receptor and interleukin 6 in prostate carcinoma cells.
Siegall, C. B., Schwab, G., Nordan, R. P., FitzGerald, D. J., & Pastan, I. (1990) · PubMed · Cited by 153
Interleukin-6 functions as an autocrine growth factor in human bladder carcinoma cell linesin vitro
Okamoto, M., Hattori, K., & Oyasu, R. (1997) · International Journal of Cancer · Cited by 112
Kalogeris, T. J., Laroux, F. S., Cockrell, A. S., Ichikawa, H., Okayama, N., Phifer, T. J., Alexander, J. S., & Grisham, M. B. (1999) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.1999.276.4.c856 · Cited by 82
Cited by
Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives
Chen, D., Frezza, M., Schmitt, S., Kanwar, J., & P. Dou, Q. (2011) · Current Cancer Drug Targets · doi:10.2174/156800911794519752 · Cited by 795
Kuhn, D. J., Chen, Q., Voorhees, P. M., Strader, J. S., Shenk, K. D., Sun, C. M., Demo, S. D., Bennett, M. K., van Leeuwen, F. W. B., Chanan-Khan, A. A., et al. (2007) · Blood · doi:10.1182/blood-2007-01-065888 · Cited by 768
Antitumor Activity of PR-171, a Novel Irreversible Inhibitor of the Proteasome
Demo, S. D., Kirk, C. J., Aujay, M. A., Buchholz, T. J., Dajee, M., Ho, M. N., Jiang, J., Laidig, G. J., Lewis, E. R., Parlati, F., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4086 · Cited by 678
Richardson, P. G., Briemberg, H., Jagannath, S., Wen, P. Y., Barlogie, B., Berenson, J., Singhal, S., Siegel, D. S., Irwin, D., Schuster, M., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.7779 · Cited by 649
Self-citationProteasome Inhibitors in Cancer Therapy: Lessons from the First Decade
Orlowski, R. Z., & Kuhn, D. J. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-2218 · Cited by 578
Metadata
- Authors
- Papandreou, C. N., Daliani, D. D., Nix, D., Yang, H., Madden, T., Wang, X., Pien, C. S., Millikan, R. E., Tu, S.-M., Pagliaro, L., Kim, J., Adams, J., Elliott, P., Esseltine, D., Petrusich, A., Dieringer, P., Perez, C., & Logothetis, C. J.
- Venue
- Journal of Clinical Oncology
- Published
- 2004-06-01
- Volume
- 22
- Issue
- 11
- Pages
- 2108-2121
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2122684890
- Cited by
- 434
- References
- 35
- FWCI
- 34.09
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.